Jack Birch Unit for Molecular Carcinogenesis, Department of Biology, Heslington, York, UK; York Biomedical Research Institute, University of York, Heslington, York, UK.
Jack Birch Unit for Molecular Carcinogenesis, Department of Biology, Heslington, York, UK; York Biomedical Research Institute, University of York, Heslington, York, UK.
Eur Urol. 2020 Aug;78(2):143-147. doi: 10.1016/j.eururo.2020.03.049. Epub 2020 Apr 27.
Disparity between genome-wide mutations in bladder and other cancers where smoking is a risk factor raises questions about carcinogenesis in different epithelia. To develop an experimental model of bladder carcinogenesis, we clonally expanded in vitro differentiated normal human urothelial (NHU) cells following exposure to an exemplar procarcinogen and used whole-genome DNA sequencing to derive mutational signatures. Benzo[a]pyrene (BaP) was activated by endogenous cytochrome P450 (cytochrome P450 family 1 subfamily A member 1 [CYP1A1]) to create genomically modified NHU cells. Comparison with the Catalogue of Somatic Mutations in Cancer (COSMIC) showed that mutations induced by BaP in NHU cells were similar to smoking-associated signatures in bladder and other cancers, including single- and doublet-base substitution signatures characterised by C > A transversions (COSMIC_SBS4 and COSMIC_DBS2, respectively), and an insertion/deletion signature of C deletions in homopolymer regions (COSMIC ID3). Our study provides the first direct evidence that BaP is activated locally in the urothelium, initiating the well-described smoking-associated mutational signatures. An absence of other common bladder cancer (BLCA)-associated genomic signatures points strongly to other primary causes of BLCA, which the new experimental approach described here is well placed to investigate. Mutational signatures ignore whether genes are affected, but tissue-specific drivers (KMT2D, KMT2C, and CDKN1A) were significantly overmutated in this model, providing insight on the emergent selection pressures. PATIENT SUMMARY: In a carefully controlled laboratory setting, we exposed normal human urothelial tissues to a procarcinogen (benzo[a]pyrene) found in cigarette smoke. We show that the urothelial tissues activated the carcinogen and led to mutations forming across the genome in a characteristic pattern. This particular "mutational signature" is found in bladder tumours and other smoking-induced cancers (eg, lung); however, our study highlights that there are other unknown mutational processes in bladder cancer that is not the direct result of smoke carcinogens, and this will require further investigation.
在膀胱癌和其他与吸烟有关的癌症中,全基因组突变的差异引发了对不同上皮细胞致癌作用的疑问。为了开发膀胱癌发生的实验模型,我们在体外对暴露于范例前致癌物的分化正常的人尿路上皮(NHU)细胞进行了克隆扩增,并使用全基因组 DNA 测序来推导突变特征。苯并[a]芘(BaP)被内源性细胞色素 P450(细胞色素 P450 家族 1 亚家族 A 成员 1 [CYP1A1])激活,从而产生基因组修饰的 NHU 细胞。与癌症体细胞突变目录(COSMIC)的比较表明,BaP 在 NHU 细胞中诱导的突变与膀胱癌和其他癌症中的吸烟相关特征相似,包括由 C> A 颠换(COSMIC_SBS4 和 COSMIC_DBS2)和特征的单碱基和双碱基替换特征以及在同源多聚体区域的 C 缺失插入缺失特征(COSMIC ID3)。我们的研究首次直接证明 BaP 在尿路上皮局部被激活,引发了众所周知的与吸烟相关的突变特征。缺乏其他常见的膀胱癌(BLCA)相关基因组特征强烈指向 BLCA 的其他主要原因,而这里描述的新实验方法非常适合对此进行研究。突变特征忽略了基因是否受到影响,但在该模型中,组织特异性驱动基因(KMT2D、KMT2C 和 CDKN1A)明显过突变,为新兴的选择压力提供了深入了解。患者总结:在精心控制的实验室环境中,我们将正常的人尿路上皮组织暴露于香烟烟雾中发现的前致癌物(苯并[a]芘)。我们表明,尿路上皮组织激活了致癌物质,并导致整个基因组中形成特征性的突变模式。这种特殊的“突变特征”存在于膀胱癌和其他与吸烟有关的癌症中(例如,肺癌);然而,我们的研究强调,膀胱癌中存在其他未知的突变过程,而不是烟雾致癌物的直接结果,这需要进一步调查。